Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 6, 2009, Pages 1299-1300

  Odero, Randy O ^a   Cleveland, Kerry O ^a   Gelfand, Michael S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Creatine phosphokinase; Interstitial nephritis; Linezolid; Simvastatin

Indexed keywords

CEFEPIME; CIPROFLOXACIN; DAPTOMYCIN; ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFUSION FLUID; LINEZOLID; MINOCYCLINE; NICOTINIC ACID; SIMVASTATIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ARTHROPLASTY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FALLING; FEMUR FRACTURE; HUMAN; LEG PAIN; LETTER; LEUKOCYTE COUNT; LIMB PAIN; PAIN; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; REOPERATION; RHABDOMYOLYSIS; SIDE EFFECT; WEAKNESS;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, ACUTE; RHABDOMYOLYSIS;

EID: 65749104822     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp127     Document Type: Letter

References (13)

1. Tunkel AR, Scheld WM. Acute meningitis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. Philadelphia, PA: Elsevier, Inc., 2005; 1083-126.
2. Fong IW, Tomkins KB. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7: 604-12.
3. Carmeli Y, Troillet N, Eliopoulos GM et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-82.
4. Tunkel AR, Kaufman BA. Cerebrospinal fluid shunt infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. Philadelphia, PA: Elsevier, Inc., 2005; 1126-32.
5. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: A systematic review of the available evidence. Int J Antimicrob Agents 2007; 29: 9-25.
6. Isaacs D, Slack MP, Wilkinson AR et al. Successful treatment of Pseudomonas ventriculitis with ciprofloxacin. J Antimicrob Chemother 1986; 17: 535-8.
7. Matthews SJ, Lancaster JW. Doripenem monohydrate, a broadspectrum carbapenem antibiotic. Clin Ther 2009; 31: 42-63.
8. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 3086-92.
9. Sakyo S, Tomita H, Tanimoto K et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. J Antibiot (Tokyo) 2006; 59: 220-8.
10. Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis 2006; 55: 241-3.
11. Pillar CM, Torres MK, Brown NP et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008; 52: 4388-99.
12. Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 2009; 63: 426-33.
13. Horiuchi M, Kimura M, Tokumura M et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 2006; 222: 114-24.